Multiple Sclerosis - Pipeline Review, H1 2018

Global Markets Direct
789 Pages - GMD17579
$2,500.00

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Sclerosis - Pipeline Review, H1 2018, provides an overview of the Multiple Sclerosis (Central Nervous System) pipeline landscape.

Multiple sclerosis (MS) is a potentially debilitating disease in which body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between brain, spinal cord and other areas of body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of body, fatigue and slurred speech. The predisposing factors include age, gender, family history and certain infections.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple Sclerosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Multiple Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 9, 24, 29, 157, 36 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 4 and 41 molecules, respectively.

Multiple Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Sclerosis (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Multiple Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Multiple Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Multiple Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Sclerosis (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Multiple Sclerosis (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Multiple Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

4D Pharma PLC
AB Science SA
AbbVie Inc
Abion Inc
Abzena Plc
Acorda Therapeutics Inc
Actelion Pharmaceuticals Ltd
Addex Therapeutics Ltd
Adhaere Pharmaceuticals Inc
Aegis Therapeutics LLC
Affectis Pharmaceuticals AG
AiCuris GmbH & Co KG
Alpha Cancer Technologies Inc
Amarna Therapeutics BV
Anavex Life Sciences Corp
Antisense Therapeutics Ltd
Antoxis Ltd
Aphios Corp
Apitope International NV
Arven Ilac
AstraZeneca Plc
Atara Biotherapeutics Inc
Athersys Inc
Atlantic Bio Sci LLC
Axxam SpA
Baliopharm AG
BioApex sro
Biocad
Biocon Ltd
Biogen Inc
BioHealthonomics Inc
Biond Biologics Ltd
Bionovis SA
Bionure Farma SL
Biovista Inc
Bolder Biotechnology Inc
Boston Pharmaceuticals Inc
BrainStorm Cell Therapeutics Inc
Bristol-Myers Squibb Co
BTB Pharma AB
CASI Pharmaceuticals Inc
Celgene Corp
Cell2B Advanced Therapeutics SA
Cellix Bio Pvt Ltd
Cinnagen Co
Cognosci Inc
Coherus BioSciences Inc
Commence Bio Inc
Complement Pharma BV
Compugen Ltd
Cotinga Pharmaceuticals Inc
CuraVac Inc
Cyxone AB
DanDrit Biotech A/S
Denceptor Therapeutics Ltd
Domain Therapeutics SA
Eli Lilly and Co
Endece LLC
Evgen Pharma Plc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
FPRT Bio Inc
Gemac SA
Genervon Biopharmaceuticals LLC
GeNeuro SA
Gilead Sciences Inc
GlaxoSmithKline Plc
Glialogix Inc
Gliknik Inc
GlyTag LLC
Hansa Medical AB
Harbor Therapeutics Inc
Humanigen Inc
ImCyse SA
Immune Response BioPharma Inc
Immungenetics AG
Immunwork Inc
Inception Sciences Inc
Io Therapeutics Inc
Istesso Ltd
Johnson & Johnson
Jyant Technologies Inc
Kadimastem Ltd
Kadmon Corp LLC
KAHR medical Ltd
Karo Pharma AB
Kyorin Pharmaceutical Co Ltd
Lead Discovery Center GmbH
LFB SA
Lipocure Ltd
Longevity Biotech Inc
M3 Biotechnology Inc
Mapi Pharma Ltd
Maruho Co Ltd
MedAnnex Ltd
MedDay SA
Merck KGaA
Meta-IQ ApS
Mitochon Pharmaceuticals Inc
Mitotech SA
Mitsubishi Tanabe Pharma Corp
Mochida Pharmaceutical Co Ltd
Momenta Pharmaceuticals Inc
MorphoSys AG
Mount Tam Biotechnologies Inc
Neuren Pharmaceuticals Ltd
Neurofx Inc
Neuronax SAS
New World Laboratories Inc
Novartis AG
Nuevolution AB
Numab Innovation AG
Ogeda SA
Omeros Corp
OncoImmune Inc
Oryzon Genomics SA
OSE Immunotherapeutics
Pangen Biotech Inc.
Parvus Therapeutics Inc
Pfizer Inc
Principia Biopharma Inc
ProNoxis AB
Quimatryx SL
ReceptoPharm Inc
RedHill Biopharma Ltd
RegeneRx Biopharmaceuticals Inc
Renovo Neural Inc
Resverlogix Corp
ReveraGen BioPharma Inc
Rewind Therapeutics NV
Rhizen Pharmaceuticals SA
Rigel Pharmaceuticals Inc
Rodos BioTarget GmbH
Rubius Therapeutics Inc
SanBio Inc
Sanofi
Sareum Holdings Plc
Senju Pharmaceutical Co Ltd
Sorrento Therapeutics Inc
Synthon Holdings BV
Teikoku Pharma USA Inc
Tetra Discovery Partners LLC
Teva Pharmaceutical Industries Ltd
Tiziana Life Sciences Plc
Toleranzia AB
TolerogenixX GmbH
Topas Therapeutics GmbH
TxCell SA
Vaccinex Inc
Vakzine Projekt Management GmbH
Vicore Pharma AB
Vitality Biopharma Inc
Yeda Research and Development Company Ltd

'

Table of Contents
Table of Contents 2
Introduction 10
Multiple Sclerosis - Overview 11
Multiple Sclerosis - Therapeutics Development 12
Multiple Sclerosis - Therapeutics Assessment 48
Multiple Sclerosis - Companies Involved in Therapeutics Development 70
Multiple Sclerosis - Drug Profiles 135
Multiple Sclerosis - Discontinued Products 743
Multiple Sclerosis - Product Development Milestones 746
Appendix 758

List of Tables
Number of Products under Development for Multiple Sclerosis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..7), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..8), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..9), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..10), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Products under Development by Companies, H1 2018 (Contd..6), H1 2018
Products under Development by Companies, H1 2018 (Contd..7), H1 2018
Products under Development by Companies, H1 2018 (Contd..8), H1 2018
Products under Development by Companies, H1 2018 (Contd..9), H1 2018
Products under Development by Companies, H1 2018 (Contd..10), H1 2018
Products under Development by Companies, H1 2018 (Contd..11), H1 2018
Products under Development by Companies, H1 2018 (Contd..12), H1 2018
Products under Development by Companies, H1 2018 (Contd..13), H1 2018
Products under Development by Companies, H1 2018 (Contd..14), H1 2018
Products under Development by Universities/Institutes, H1 2018
Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018 (Contd..2), H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..5), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..6), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..7), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..4), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..5), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..6), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..7), H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Multiple Sclerosis - Pipeline by 4D Pharma PLC, H1 2018
Multiple Sclerosis - Pipeline by AB Science SA, H1 2018
Multiple Sclerosis - Pipeline by AbbVie Inc, H1 2018
Multiple Sclerosis - Pipeline by Abion Inc, H1 2018
Multiple Sclerosis - Pipeline by Abzena Plc, H1 2018
Multiple Sclerosis - Pipeline by Acorda Therapeutics Inc, H1 2018
Multiple Sclerosis - Pipeline by Actelion Pharmaceuticals Ltd, H1 2018
Multiple Sclerosis - Pipeline by Addex Therapeutics Ltd, H1 2018
Multiple Sclerosis - Pipeline by Adhaere Pharmaceuticals Inc, H1 2018
Multiple Sclerosis - Pipeline by Aegis Therapeutics LLC, H1 2018
Multiple Sclerosis - Pipeline by Affectis Pharmaceuticals AG, H1 2018
Multiple Sclerosis - Pipeline by AiCuris GmbH & Co KG, H1 2018
Multiple Sclerosis - Pipeline by Alpha Cancer Technologies Inc, H1 2018
Multiple Sclerosis - Pipeline by Amarna Therapeutics BV, H1 2018
Multiple Sclerosis - Pipeline by Anavex Life Sciences Corp, H1 2018
Multiple Sclerosis - Pipeline by Antisense Therapeutics Ltd, H1 2018
Multiple Sclerosis - Pipeline by Antoxis Ltd, H1 2018
Multiple Sclerosis - Pipeline by Aphios Corp, H1 2018
Multiple Sclerosis - Pipeline by Apitope International NV, H1 2018
Multiple Sclerosis - Pipeline by Arven Ilac, H1 2018
Multiple Sclerosis - Pipeline by AstraZeneca Plc, H1 2018
Multiple Sclerosis - Pipeline by Atara Biotherapeutics Inc, H1 2018
Multiple Sclerosis - Pipeline by Athersys Inc, H1 2018
Multiple Sclerosis - Pipeline by Atlantic Bio Sci LLC, H1 2018
Multiple Sclerosis - Pipeline by Axxam SpA, H1 2018
Multiple Sclerosis - Pipeline by Baliopharm AG, H1 2018
Multiple Sclerosis - Pipeline by BioApex sro, H1 2018
Multiple Sclerosis - Pipeline by Biocad, H1 2018
Multiple Sclerosis - Pipeline by Biocon Ltd, H1 2018
Multiple Sclerosis - Pipeline by Biogen Inc, H1 2018
Multiple Sclerosis - Pipeline by BioHealthonomics Inc, H1 2018
Multiple Sclerosis - Pipeline by Biond Biologics Ltd, H1 2018
Multiple Sclerosis - Pipeline by Bionovis SA, H1 2018
Multiple Sclerosis - Pipeline by Bionure Farma SL, H1 2018
Multiple Sclerosis - Pipeline by Biovista Inc, H1 2018
Multiple Sclerosis - Pipeline by Bolder Biotechnology Inc, H1 2018
Multiple Sclerosis - Pipeline by Boston Pharmaceuticals Inc, H1 2018
Multiple Sclerosis - Pipeline by BrainStorm Cell Therapeutics Inc, H1 2018
Multiple Sclerosis - Pipeline by Bristol-Myers Squibb Co, H1 2018
Multiple Sclerosis - Pipeline by BTB Pharma AB, H1 2018
Multiple Sclerosis - Pipeline by CASI Pharmaceuticals Inc, H1 2018
Multiple Sclerosis - Pipeline by Celgene Corp, H1 2018
Multiple Sclerosis - Pipeline by Cell2B Advanced Therapeutics SA, H1 2018
Multiple Sclerosis - Pipeline by Cellix Bio Pvt Ltd, H1 2018
Multiple Sclerosis - Pipeline by Cinnagen Co, H1 2018
Multiple Sclerosis - Pipeline by Cognosci Inc, H1 2018
Multiple Sclerosis - Pipeline by Coherus BioSciences Inc, H1 2018
Multiple Sclerosis - Pipeline by Commence Bio Inc, H1 2018
Multiple Sclerosis - Pipeline by Complement Pharma BV, H1 2018
Multiple Sclerosis - Pipeline by Compugen Ltd, H1 2018
Multiple Sclerosis - Pipeline by Cotinga Pharmaceuticals Inc, H1 2018
Multiple Sclerosis - Pipeline by CuraVac Inc, H1 2018
Multiple Sclerosis - Pipeline by Cyxone AB, H1 2018
Multiple Sclerosis - Pipeline by DanDrit Biotech A/S, H1 2018
Multiple Sclerosis - Pipeline by Denceptor Therapeutics Ltd, H1 2018
Multiple Sclerosis - Pipeline by Domain Therapeutics SA, H1 2018
Multiple Sclerosis - Pipeline by Eli Lilly and Co, H1 2018
Multiple Sclerosis - Pipeline by Endece LLC, H1 2018
Multiple Sclerosis - Pipeline by Evgen Pharma Plc, H1 2018
Multiple Sclerosis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Multiple Sclerosis - Pipeline by Fate Therapeutics Inc, H1 2018
Multiple Sclerosis - Pipeline by FPRT Bio Inc, H1 2018
Multiple Sclerosis - Pipeline by Gemac SA, H1 2018
Multiple Sclerosis - Pipeline by Genervon Biopharmaceuticals LLC, H1 2018
Multiple Sclerosis - Pipeline by GeNeuro SA, H1 2018
Multiple Sclerosis - Pipeline by Gilead Sciences Inc, H1 2018
Multiple Sclerosis - Pipeline by GlaxoSmithKline Plc, H1 2018
Multiple Sclerosis - Pipeline by Glialogix Inc, H1 2018
Multiple Sclerosis - Pipeline by Gliknik Inc, H1 2018
Multiple Sclerosis - Pipeline by GlyTag LLC, H1 2018
Multiple Sclerosis - Pipeline by Hansa Medical AB, H1 2018
Multiple Sclerosis - Pipeline by Harbor Therapeutics Inc, H1 2018
Multiple Sclerosis - Pipeline by Humanigen Inc, H1 2018
Multiple Sclerosis - Pipeline by ImCyse SA, H1 2018
Multiple Sclerosis - Pipeline by Immune Response BioPharma Inc, H1 2018
Multiple Sclerosis - Pipeline by Immungenetics AG, H1 2018
Multiple Sclerosis - Pipeline by Immunwork Inc, H1 2018
Multiple Sclerosis - Pipeline by Inception Sciences Inc, H1 2018
Multiple Sclerosis - Pipeline by Io Therapeutics Inc, H1 2018
Multiple Sclerosis - Pipeline by Istesso Ltd, H1 2018
Multiple Sclerosis - Pipeline by Johnson & Johnson, H1 2018
Multiple Sclerosis - Pipeline by Jyant Technologies Inc, H1 2018
Multiple Sclerosis - Pipeline by Kadimastem Ltd, H1 2018
Multiple Sclerosis - Pipeline by Kadmon Corp LLC, H1 2018
Multiple Sclerosis - Pipeline by KAHR medical Ltd, H1 2018
Multiple Sclerosis - Pipeline by Karo Pharma AB, H1 2018
Multiple Sclerosis - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018
Multiple Sclerosis - Pipeline by Lead Discovery Center GmbH, H1 2018
Multiple Sclerosis - Pipeline by LFB SA, H1 2018
Multiple Sclerosis - Pipeline by Lipocure Ltd, H1 2018
Multiple Sclerosis - Pipeline by Longevity Biotech Inc, H1 2018
Multiple Sclerosis - Pipeline by M3 Biotechnology Inc, H1 2018
Multiple Sclerosis - Pipeline by Mapi Pharma Ltd, H1 2018
Multiple Sclerosis - Pipeline by Maruho Co Ltd, H1 2018
Multiple Sclerosis - Pipeline by MedAnnex Ltd, H1 2018
Multiple Sclerosis - Pipeline by MedDay SA, H1 2018
Multiple Sclerosis - Pipeline by Merck KGaA, H1 2018
Multiple Sclerosis - Pipeline by Meta-IQ ApS, H1 2018
Multiple Sclerosis - Pipeline by Mitochon Pharmaceuticals Inc, H1 2018
Multiple Sclerosis - Pipeline by Mitotech SA, H1 2018
Multiple Sclerosis - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018
Multiple Sclerosis - Pipeline by Mochida Pharmaceutical Co Ltd, H1 2018
Multiple Sclerosis - Pipeline by Momenta Pharmaceuticals Inc, H1 2018
Multiple Sclerosis - Pipeline by MorphoSys AG, H1 2018
Multiple Sclerosis - Pipeline by Mount Tam Biotechnologies Inc, H1 2018
Multiple Sclerosis - Pipeline by Neuren Pharmaceuticals Ltd, H1 2018
Multiple Sclerosis - Pipeline by Neurofx Inc, H1 2018
Multiple Sclerosis - Pipeline by Neuronax SAS, H1 2018
Multiple Sclerosis - Pipeline by New World Laboratories Inc, H1 2018
Multiple Sclerosis - Pipeline by Novartis AG, H1 2018
Multiple Sclerosis - Pipeline by Nuevolution AB, H1 2018
Multiple Sclerosis - Pipeline by Numab Innovation AG, H1 2018
Multiple Sclerosis - Pipeline by Ogeda SA, H1 2018
Multiple Sclerosis - Pipeline by Omeros Corp, H1 2018
Multiple Sclerosis - Pipeline by OncoImmune Inc, H1 2018
Multiple Sclerosis - Pipeline by Oryzon Genomics SA, H1 2018
Multiple Sclerosis - Pipeline by OSE Immunotherapeutics, H1 2018
Multiple Sclerosis - Pipeline by Pangen Biotech Inc., H1 2018
Multiple Sclerosis - Pipeline by Parvus Therapeutics Inc, H1 2018
Multiple Sclerosis - Pipeline by Pfizer Inc, H1 2018
Multiple Sclerosis - Pipeline by Principia Biopharma Inc, H1 2018
Multiple Sclerosis - Pipeline by ProNoxis AB, H1 2018
Multiple Sclerosis - Pipeline by Quimatryx SL, H1 2018
Multiple Sclerosis - Pipeline by ReceptoPharm Inc, H1 2018
Multiple Sclerosis - Pipeline by RedHill Biopharma Ltd, H1 2018
Multiple Sclerosis - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2018
Multiple Sclerosis - Pipeline by Renovo Neural Inc, H1 2018
Multiple Sclerosis - Pipeline by Resverlogix Corp, H1 2018
Multiple Sclerosis - Pipeline by ReveraGen BioPharma Inc, H1 2018
Multiple Sclerosis - Pipeline by Rewind Therapeutics NV, H1 2018
Multiple Sclerosis - Pipeline by Rhizen Pharmaceuticals SA, H1 2018
Multiple Sclerosis - Pipeline by Rigel Pharmaceuticals Inc, H1 2018
Multiple Sclerosis - Pipeline by Rodos BioTarget GmbH, H1 2018
Multiple Sclerosis - Pipeline by Rubius Therapeutics Inc, H1 2018
Multiple Sclerosis - Pipeline by SanBio Inc, H1 2018
Multiple Sclerosis - Pipeline by Sanofi, H1 2018
Multiple Sclerosis - Pipeline by Sareum Holdings Plc, H1 2018
Multiple Sclerosis - Pipeline by Senju Pharmaceutical Co Ltd, H1 2018
Multiple Sclerosis - Pipeline by Sorrento Therapeutics Inc, H1 2018
Multiple Sclerosis - Pipeline by Synthon Holdings BV, H1 2018
Multiple Sclerosis - Pipeline by Teikoku Pharma USA Inc, H1 2018
Multiple Sclerosis - Pipeline by Tetra Discovery Partners LLC, H1 2018
Multiple Sclerosis - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2018
Multiple Sclerosis - Pipeline by Tiziana Life Sciences Plc, H1 2018
Multiple Sclerosis - Pipeline by Toleranzia AB, H1 2018
Multiple Sclerosis - Pipeline by TolerogenixX GmbH, H1 2018
Multiple Sclerosis - Pipeline by Topas Therapeutics GmbH, H1 2018
Multiple Sclerosis - Pipeline by TxCell SA, H1 2018
Multiple Sclerosis - Pipeline by Vaccinex Inc, H1 2018
Multiple Sclerosis - Pipeline by Vakzine Projekt Management GmbH, H1 2018
Multiple Sclerosis - Pipeline by Vicore Pharma AB, H1 2018
Multiple Sclerosis - Pipeline by Vitality Biopharma Inc, H1 2018
Multiple Sclerosis - Pipeline by Yeda Research and Development Company Ltd, H1 2018
Multiple Sclerosis - Dormant Projects, H1 2018
Multiple Sclerosis - Dormant Projects, H1 2018 (Contd..1), H1 2018
Multiple Sclerosis - Dormant Projects, H1 2018 (Contd..2), H1 2018
Multiple Sclerosis - Dormant Projects, H1 2018 (Contd..3), H1 2018
Multiple Sclerosis - Dormant Projects, H1 2018 (Contd..4), H1 2018
Multiple Sclerosis - Dormant Projects, H1 2018 (Contd..5), H1 2018
Multiple Sclerosis - Dormant Projects, H1 2018 (Contd..6), H1 2018
Multiple Sclerosis - Dormant Projects, H1 2018 (Contd..7), H1 2018
Multiple Sclerosis - Dormant Projects, H1 2018 (Contd..8), H1 2018
Multiple Sclerosis - Dormant Projects, H1 2018 (Contd..9), H1 2018
Multiple Sclerosis - Dormant Projects, H1 2018 (Contd..10), H1 2018
Multiple Sclerosis - Dormant Projects, H1 2018 (Contd..11), H1 2018
Multiple Sclerosis - Dormant Projects, H1 2018 (Contd..12), H1 2018
Multiple Sclerosis - Dormant Projects, H1 2018 (Contd..13), H1 2018
Multiple Sclerosis - Dormant Projects, H1 2018 (Contd..14), H1 2018
Multiple Sclerosis - Dormant Projects, H1 2018 (Contd..15), H1 2018
Multiple Sclerosis - Dormant Projects, H1 2018 (Contd..16), H1 2018
Multiple Sclerosis - Dormant Projects, H1 2018 (Contd..17), H1 2018
Multiple Sclerosis - Dormant Projects, H1 2018 (Contd..18), H1 2018
Multiple Sclerosis - Discontinued Products, H1 2018
Multiple Sclerosis - Discontinued Products, H1 2018 (Contd..1), H1 2018
Multiple Sclerosis - Discontinued Products, H1 2018 (Contd..2), H1 2018

List of Figures
Number of Products under Development for Multiple Sclerosis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

$2,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838



Browse All Reports